Clinical Trials Logo

Clinical Trial Summary

A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5 and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There is evidence that both terminal complement activation (via C5) and the lipid mediator LTB4 may have a central role in driving the disease. In this study patients will be randomized to receive either nomacopan plus oral corticosteroids (OCS) or placebo plus OCS for a treatment period of 24 weeks. OCS will be tapered over the course of the treatment if the symptoms of disease improve. Part A the 4-arm study in 48 patients will compare two different doses of nomacopan with placebo and is anticipated to complete and report in March 2023. Part B the confirmatory 2-arm study in approximately 100 patients will compare a single dose of nomacopan with placebo and is anticipated to complete and report in June 2025.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05061771
Study type Interventional
Source AKARI Therapeutics
Contact Sanjeev Khindri
Phone +44 020 8004 0261
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date September 2021
Completion date June 2025

See also
  Status Clinical Trial Phase
Terminated NCT03286582 - A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Phase 2
Recruiting NCT03636763 - Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Recruiting NCT00802243 - Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Phase 2
Recruiting NCT04206553 - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Phase 2/Phase 3
Completed NCT00431119 - Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Phase 2
Recruiting NCT04563923 - Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Phase 2
Completed NCT03320798 - Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients N/A
Completed NCT03272958 - Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
Completed NCT02883894 - Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid N/A
Completed NCT00809822 - Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Phase 2
Not yet recruiting NCT04128176 - Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Phase 3
Recruiting NCT04612790 - A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. Phase 3
Completed NCT00286325 - Rituximab in the Treatment of Patients With Bullous Pemphigoid Phase 1/Phase 2
Recruiting NCT04728854 - Telederm and Bullous Pemphigoid
Recruiting NCT04117932 - Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Phase 2
Terminated NCT01571895 - Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Phase 2
Terminated NCT01688882 - Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Phase 2
Recruiting NCT02313870 - Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Phase 3
Recruiting NCT02874079 - Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid N/A
Active, not recruiting NCT01265082 - Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission N/A